Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821977 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
- 20
- Study locations
NCT00821977: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Novartis.
NCT00821977 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Novartis. The registered enrollment target is 338 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00821977, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vildagliptin
Study Locations (20)
California
- Sall Research Medical Center - Artesia
- Associated Pharmaceutical Research - Buena Park
- Providence Research - Burbank
- Burbank - Lovelace Scientific Resources, Inc. - Burbank
- Lucita M. Cruz, M.D., Inc. - Norwalk
- California Research Foundation - San Diego
- Ritchken and First MDs - San Diego
- San Diego Sports Medicine Research and Family Care - San Diego
- Crest Clinical Trials - Santa Ana
Arizona
- Horizon Clinical Research Associates, PLLC - Gilbert
- Vista Medical Research, Inc - Mesa
- Clinical Research Advantage - Mesa
- Hope Clinical Research - Phoenix
- Anasazi Internal Medicine - Phoenix
- Tatum Ridge Internal Medicine - Phoenix
- Paradigm Clinical - Tucson
- Tucson Clinical Research - Tucson
Arkansas
- Medical Investigations, Inc. - Little Rock
- Paul W. Davis, MD - Pine Bluff
Alabama
- Advanced Clinical Research - Pell City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
What the finished NCT00821977 record still lists
NCT00821977 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00821977 names 20 study sites across 4 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00821977 about?
NCT00821977 is a clinical study titled "Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes". This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.
What is the current status of trial NCT00821977?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2008-11. Estimated completion is 2010-10.
What conditions does trial NCT00821977 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00821977?
The interventions under investigation include: Placebo (DRUG), Vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00821977?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00821977 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00821977's enrollment target sits among peer trials
338 107th of 348 higher than 242 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia